Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 381-392

  Masuelli, Laura ^a   Focaccetti, Chiara ^b   Cereda, Vittore ^c   Lista, Florigio ^d   Vitolo, Domenico ^a   Trono, Paola ^c   Gallo, Pasquale ^e   Amici, Augusto ^f   Monaci, Paolo ^e   Mattei, Maurizio ^b   Modesti, Mauro ^g   Forni, Guido ^h   Kraus, Matthias H ⁱ   Muraro, Raffaella ^j   Modesti, Andrea ^c   Bei, Roberto ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b STA ^*  (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Centro Studi e Ricerche Sanità e Veterinaria Esercito   (Italy)

^e IRBM   (Italy)

^f UNIVERSITY OF CAMERINO   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j UNIVERSITY OF CHIETI   (Italy)

more..

Author keywords

Cellular immunity; Oncogene; Serum antibodies; Targeted immunotherapy; Tumor regression; Vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; CELL STRAIN 3T3; CHEMISTRY; CYTOLOGY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; PROTO ONCOGENE; RAT; TIME; TRANSGENE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CANCER VACCINES; DISEASE-FREE SURVIVAL; EPITOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NIH 3T3 CELLS; RATS; RECEPTOR, ERBB-2; TIME FACTORS; TRANSGENES;

EID: 34047253226     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
2. Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122-130, 2003.
3. Cheever MA, Disis ML, Bernhard H, et al: Immunity to oncogenic proteins. Immunol Rev 145: 33-59, 1995.
4. Purev E, Cai D, Miller E, et al: Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 173: 6472-6480, 2004.
5. Shomura H, Shichijo S, Komatsu N, et al: Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients. Eur J Cancer 40: 1776-1786, 2004. (Pubitemid 38902915)
6. Bei R, Masuelli L, Moriconi E, Visco V, Moretti A, Kraus MH and Muraro R: Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 18: 1267-1275, 1999.
7. Muller WJ, Sinn E, Pattengale PK, Fallace R and Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115, 1988.
8. Bargmann CI, Hung MC and Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986. (Pubitemid 16128785)
9. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319: 230-234, 1986. (Pubitemid 16128786)
10. Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
11. Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193-9197, 1989.
12. Plowman GD, Culouscou JM, Whitney GS, et al: Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746-1750, 1993.
13. Rovero S, Amici A, Di Carlo E, et al: DNA vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165: 5133-5142, 2000.
14. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL and Penichet ML: Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21: 1317-1326, 2003.
15. Gallo P, Dharmapuri S, Nuzzo M, et al: Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113: 67-77, 2005. (Pubitemid 39507312)
16. Park JM, Terabe M, Sakai Y, Munasinghe J, Morris JC and Berzofsky JA: Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 174: 4228-4236, 2005. (Pubitemid 40396003)
17. Nanni P, Landuzzi L, Nicoletti G, et al: Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J Immunol 173: 2288-2296, 2005.
18. Di Marco E, Pierce JH, Knicley CL and Di Fiore PP: Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol Cell Biol 10: 3247-3252, 1990. (Pubitemid 120004951)
19. Fedi P, Pierce JH, Di Fiore PP and Kraus MH: Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 14: 492-500, 1994. (Pubitemid 24013111)
20. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821, 1995.
21. Kraus MH, Fedi P, Starks V, Muraro R and Aaronson SA: Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90: 2900-2904, 1993. (Pubitemid 23113525)
22. Baulida J, Kraus MH, Alimandi M, Di Fiore PP and Carpenter G: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251-5257, 1996. (Pubitemid 26075021)
23. Bei R, Moretti A, Visco V, De Filippi R, Tsang KY, Frati L and Muraro R: Cell mediated cytotoxicity of human colon carcinoma cells by a monoclonal antibody (R4) recognizing the carcinoembryonic antigen (CEA) and CEA-related molecules. Int J Oncol 8: 1127-1135, 1996.
24. Bei R, Pompa G, Vitolo D, et al: Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 195: 343-348, 2001.
25. Masuelli L, Bei R, Sacchetti P, et al: Beta-catenin accumulates in intercalated disks of hypertrophic cardiomyopathic hearts. Cardiovasc Res 60: 376-387, 2003.
26. Bei R, Kantor J, Kashmiri SVS, Abrams S and Schlom J: Enhanced immune response and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with recombinant vaccinia CEA. J Immunother 16: 275-282, 1994.
27. Amici A, Venanzi FM and Concetti A: Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 47: 183-190, 1998.
28. Sung MW, Nagashima S, Johnson JT, Van Dongen GA and Whiteside TL: The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayer of human squamous cell carcinoma of head and neck targets. Cell Immunol 171: 20-29, 1996.
29. Yip YL, Smith G, Koch J, Dubel S and Ward RL: Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB2 monoclonal antibodies: implication for vaccine design. J Immunol 166: 5271-5278, 2001.
30. Bei R, Guptill V, Masuelli L, et al: The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J Immunother 21: 159-169, 1998.
31. Motulsky HJ: Prism4 Statistics Guide. Statistical analyses for laboratory and clinical researchers. GraphPad Software Inc. 2003, San Diego, CA.
32. Srinivasan R, Gillett CE, Barnes DM and Gullick WJ: Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 60: 1483-1487, 2000. (Pubitemid 30183410)
33. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002. (Pubitemid 34111379)
34. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
35. Nahta R and Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138, 2006.
36. Disis ML and Schiffman K: Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28 (6 Suppl 18): 12-20, 2001.
37. Nahta R, Hung MC and Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346, 2004.
38. Weber LW, Bowne WB, Wolchok JD, et al: Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102: 1258-1264, 1998.
39. Su JM, Wei YQ, Tian L, et al: Active immunogen therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 63: 600-607, 2003.
40. Disis ML, Shiota FM and Cheever MA: Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 93: 192-199, 1998.
41. Srinivasan R, Houghton AN and WolcHok JD: Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immunity 2: 8-17, 2002.
42. He Q, Wei Y, Tian L, et al: Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 278: 21831-21836, 2003.
43. Wei YQ: Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. Anticancer Drugs 13: 229-235, 2002.
44. Carpenter G: Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 15: 143-148, 2003.
45. Jones FE, Golding JP and Gassmann M: ErbB4 signaling during breast and neural development: novel genetic models reveal unique ErbB4 activities. Cell Cycle 2: 555-559, 2003.
46. Jones FE, Welte T, Fu XY and Stern DF: ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 147: 77-88, 1999. (Pubitemid 30211798)
47. Jackson-Fisher AJ, Bellinger G, Shum E, et al: Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene. May 1 (Epub ahead of print), 2006.
48. Nanni P, Nicoletti G, De Giovanni C, et al: Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194: 1195-1205, 2001.
49. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC and Kaumaya PT: Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 60: 3782-3789, 2000.
50. Montgomery RB, Makary E, Schiffman K, Goodell V and Disis ML: Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65: 650-656, 2005.
51. Brodowicz T, Kandioler D, Tomek S, et al: Anti-HER-2/neu antibody induces apoptosis in HER-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer 85: 1764-1770, 2001.
52. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1 and antitumor action. Cancer Res 62: 4132-4141, 2002.
53. Cuello M, Ettenberg SA, Clark AS, et al: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900, 2001.
54. Ye D, Mendelsohn J and Fan Z: Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a humanmouse chimeric anti-EGF receptor mAb C225. Oncogene 18: 731-738, 1999.
55. Reilly RT, Machiels JP, Emens LA, et al: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61: 880-883, 2001.
56. Musiani P, Allione A, Modica A, et al: Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 74: 146-157, 1996.
57. Blankenstein T and Qin Z: The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 15: 148-154, 2003.
58. Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM and Cambell MJ: Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 47: 337-342, 1999.
59. Bei R, Budillon A, Masuelli L, et al: Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 204: 317-325, 2004.
60. Wei WZ, Morris GP and Kong YM: Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53: 73-78, 2004.
61. Antony PA, Piccirillo CA, Akpinarli A, et al: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174: 2591-2601, 2005.